EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Novel Modified Bu/Vp16/cy/Flu/Ara‐C Conditioning Regimen Enhances Outcomes for High‐Risk Acute Lymphoblastic Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Xiaoyan Zhao, Yifan Yao, Yan Sun, Ziwei Xu, Aiguo Liu, Xin Dong, Huafang Wang

Cancer Medicine · 2026-03 · 15 (3)

DOI: 10.1002/cam4.71669 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 28.02.2026. Verfasst von Xiaoyan Zhao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Hematopoietic Stem Cell Transplantation, Transplantation Conditioning, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Beijing Medical Award Foundation, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) effectively treats high‐risk acute lymphoblastic leukemia (ALL), yet challenges persist due to post‐transplant relapse and conditioning regimen toxicities. The determination of an appropriate preconditioning regimen is critical to improving patient outcomes. In our transplant center, we have modified the traditional busulfan (Bu)/cyclophosphamide (Cy)/etoposide (Vp16) protocol by adding fludarabine (Flu) and cytarabine (Ara‐C), while reducing the dosage of Cy. This novel modification seeks to enhance transplantation outcomes for ALL patients.

Methods

This study retrospectively collected clinical data from 88 high‐risk ALL patients who received transplantation from June 2018 to December 2023. Among these patients, 40 received the novel modified Bu/Cy/Vp16/Flu/Ara‐C conditioning protocol, while 48 received the traditional Bu/Cy/Vp16 regimen and served as a control group.

Results

This study demonstrated a notably reduced incidence of cardiac toxicity in patients treated with the modified Bu/Cy/Vp16/Flu/Ara‐C conditioning compared to those on the traditional Bu/Cy/Vp16 regimen. Furthermore, other types of conditioning‐related toxicities were within acceptable limits in the modified regimen group. Regarding efficacy, the Bu/Cy/Vp16/Flu/Ara‐C protocol significantly reduced the cumulative two‐year relapse rate in high‐risk ALL patients compared to the Bu/Cy/Vp16 scheme (38.7% (20.9%–52.5%) vs. 11.8% (0.2%–22.1%), p = 0.017). The modified regimen showed significant improvements in 2‐year overall survival at 71.6% (57.1%–89.6%) compared to 50.6% (38%–67.3%) ( p = 0.048), and in two‐year disease‐free survival at 66.7% (51.9%–85.6%) compared to 45.3% (33.1%–62.1%) ( p = 0.015). Transplant‐related mortality was comparable between the two groups. A subgroup analysis based on disease status (CR1 and ≥ CR2) revealed that high‐risk ALL patients on the modified regimen had lower relapse rates and significantly better OS and DFS than those on the Bu/Cy/Vp16 scheme.

Conclusions

The novel modified Bu/Cy/Vp16/Flu/Ara‐C conditioning significantly enhances the prognosis of high‐risk ALL patients receiving transplantation, especially those in CR1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaHematopoietic Stem Cell TransplantationTransplantation ConditioningAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleBusulfanCyclophosphamideVidarabineCytarabineRetrospective StudiesAdultAdolescentTransplantation, HomologousEtoposideChildYoung AdultChild, PreschoolMiddle AgedTreatment Outcome

Stichwörter der Autor:innen

acute lymphoblastic leukemiaconditioning regimenrelapsetransplantation

Substanzen

BusulfanCyclophosphamideVidarabineCytarabinefludarabineEtoposide

Autor:innen und Institutionen

  • Institute of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Institute of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Förderung

  • the Beijing Medical Award Foundation, China

Zitieren

APA

Zhao, X., Yao, Y., Sun, Y., Xu, Z., Liu, A., Dong, X., & Wang, H. (2026). A Novel Modified Bu/Vp16/cy/Flu/Ara‐C Conditioning Regimen Enhances Outcomes for High‐Risk Acute Lymphoblastic Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Cancer Medicine, 15(3). https://doi.org/10.1002/cam4.71669

Vancouver

Zhao X, Yao Y, Sun Y, Xu Z, Liu A, Dong X, et al. A Novel Modified Bu/Vp16/cy/Flu/Ara‐C Conditioning Regimen Enhances Outcomes for High‐Risk Acute Lymphoblastic Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Cancer Medicine. 2026;15(3). doi:10.1002/cam4.71669

BibTeX
@article{Zhao2026,
  author = {Zhao, Xiaoyan and Yao, Yifan and Sun, Yan and Xu, Ziwei and Liu, Aiguo and Dong, Xin and Wang, Huafang},
  title = {A Novel Modified Bu/Vp16/cy/Flu/Ara‐C Conditioning Regimen Enhances Outcomes for High‐Risk Acute Lymphoblastic Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {3},
  doi = {10.1002/cam4.71669}
}
Kostenlos starten →